期刊文献+

恶性高血压患者补体因子H测定及其意义 被引量:4

The significance of complement factor H in patients with malignant hypertension
原文传递
导出
摘要 目的 通过对恶性高血压患者血清及尿液中补体因子H(CFH)的半定量分析,探讨CFH在恶性高血压发病中的作用及其临床意义.方法 选取恶性高血压肾损害患者18例,原发性高血压患者17例以及同期健康查体的正常人16例(对照组).采用双抗体夹心酶联免疫吸附(ELISA)法测定血清及尿液中CFH的浓度,同时收集临床生化及尿蛋白等临床指标.结果 恶性高血压患者血清及尿液CFH均明显高于原发性高血压组及对照组,差异有统计学意义(P<0.05),原发性高血压组与对照组比较差异无统计学意义(P>0.05);恶性高血压组患者血清CFH水平与肌酐、尿液CFH、尿蛋白浓度呈正相关(r=0.786,P<0.01;r=0.508,P<0.05;r =0.705,P<0.01).结论 恶性高血压患者CFH可能参与其肾损伤的病理过程. Objective To investigate the role of complement factor H (CFH) on the pathogenesis of malignant hypertension and its clinical significance in patients with malignant hypertension. Methods We measured the level of CFH in the serum and urine, using double antibody sandwich enzyme-linked im- munosorbent assay (ELISA) in 18 patients with malignant hypertension, 17 patients with hypertension, and 16 normal controls. Results The level of CFH in serum and urine in patients with malignant hypertension was significantly higher than that in patients with hypertension and normal control group, the difference was statistically significant( P 〈0.05 ). The level of CFH in serum was positively correlated with the level of serum creatinine, CFH in urine and the concentration of Urine protein specifically (r = 0. 786, P 〈 0.01 ; r=0. 508,P〈0. 05;r=O. 705,P〈0. 01). Conclusion Complement factor H might play a role in the pathogenesis of kidney injury in patients with malignant hypertension.
出处 《临床内科杂志》 CAS 2014年第11期745-747,共3页 Journal of Clinical Internal Medicine
基金 山东省自然科学基金资助项目,青岛市科技局应用基础研究项目
关键词 恶性高血压 补体 Malignant hypertension Complement Complement factor H
  • 相关文献

参考文献10

  • 1Dragon-Durey MA, Blanc C, Gamier A, et al. Anti-factor H autoanti- body-associated hemolytic uremic syndrome:review of literature of the autoimmune form of HUS [ J ]. Semin Thromb Hemost, 2010,36 ( 6 ) : 633 -640.
  • 2Wang FM, Yu F, Tan Y, et al. Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis [ J ]. Rheumatology, 2012,51 ( 12 ) :2269 -2277.
  • 3Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic mi- croangiopathy in lupus nephritis [ J ]. Arthritis Res Ther, 2013, 15 (1) :R12.
  • 4刘万里,薛茜,曹明芹,马金凤.用SPSS实现完全随机设计多组比较秩和检验的多重比较[J].地方病通报,2007,22(2):27-29. 被引量:95
  • 5Roumenina LT, Loirat C, Dragun-Durey MA, et al. Alternative comple- ment pathway assessment in patients with atypical HUS [ J ]. J Immunol Methods,2011,365(1-2) :8-26.
  • 6Kavanagh D, Anderson HE. Interpretation of genetic variants of uncer- tain significance in atypical hemolytic uremic syndrome [ J ]. Kidney Int,2012,81 ( 1 ) : 11-13.
  • 7Kavanagh D, Goodship T. Genetics and complement in atypical HUS [ J 1. Pediatr Nephro1,2010 ,25 (12) :2431-2442.
  • 8Oksjoki R, Jarva H, Kovanen PT, et al. Association between complement factor H and proteoglycans in early human coronary atberoselerotic le- sions implications for local regulation of complement activation[ J ~. Ar- lcrioscler Thromb Vasc Biol,2003,23 (4) :630-636.
  • 9Jozsi M ,Manuelian T, Heinen S, et al. Attachment of the soluble com- plement regulator factor H to cell and tissue surfaces:relevance for pa- thology [ J]. Histol Histopatho1,2004,19 ( 1 ) :251-258.
  • 10Uslu-GOkeeo g lu A, Do g an ~S, ~omak E, et al. Atypical hemolytic ure- mic syndrome due to factor H autoantibody[ J]. The Turkish Journal of Pediatrics ,2013,55 (1) :86-89.

二级参考文献3

  • 1阮桂海 蔡建平 建瓴.SAS统计分析实用大全[M].北京:清华大学出版社,2002..
  • 2Douglas CE.Multiple Comparisons:Philosophies and Illustrations[J].Am J Physiol Regul Integr Comp Phusiol,2000,279(I):1-8.
  • 3孙振球,徐勇勇.易学统计学[M].北京:人民卫生出版社,2002.130-133.

共引文献94

同被引文献49

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部